Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Affiliations

• ¹ Department of Oncology, Qinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing, China.
• ² Department of Oncology, Tongji University Shanghai East Hospital, Shanghai, China. lijin@csco.org.cn.
• ³ Department of Abdominal Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
• ⁴ Department of Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
• ⁵ Department of Hematology and Oncology, Taizhou First People's Hospital, Taizhou, China.
• ⁶ Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
• ⁷ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
• ⁸ Department of Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
• ⁹ Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China.
• ¹⁰ Chemotherapeutic Department, Zhongshan City People's Hospital, Zhongshan, China.
• ¹¹ Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
• ¹² Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
• ¹³ Cancer Center, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China.
• ¹⁴ Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
• ¹⁵ Department of Gastrointestinal Oncology, The First People's Hospital of Foshan, Foshan, China.
• ¹⁶ Shanghai Henlius Biotech, Inc., Shanghai, China.